BUSINESS
Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle?
The Suven Life chairman is staking his fortune on a risky but potentially game-changing pipeline of central nervous system drugs, which are notoriously difficult to develop
BUSINESS
Gennova, CEPI ink pact to develop AI-enhanced Nipah vaccine with $13.4 million funding
At present, there is no approved vaccine or specific treatment exist for the virus, which has a mortality rate of 75 percent.
BUSINESS
FICCI caution members as US indict firms dealing in fentanyl precursors
The U.S. Department of Justice alleges that the companies facilitated the transportation, concealment, and sale of these substances within the US, in violation of federal law.
BUSINESS
Fentanyl: An explainer on the deadly opioid, Trump’s war and India's role
India with its vast pharmaceutical and chemical industries is an emerging source for fentanyl precursor chemicals. Mexican cartels purchase the precursors to make fentanyl which is shipped to the US.
BUSINESS
Delhi HC restrains Natco Pharma from launching generic of Roche's rare disease drug
"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche Pharma India spokesperson told Moneycontrol.
BUSINESS
Less than 1% of health claims in India are for mental health, report reveals
The finding was part of Marsh McLennan’s "RiseUP for a Better Tomorrow" Mental Health Report 2025
BUSINESS
Eli Lilly’s weight loss drug remains expensive for most Indians despite local pricing
Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is yet to be officially recognised as a disease here. This also keeps it out of reach for the average Indian.
BUSINESS
Delhi HC denies stay against Natco Pharma, potentially paving way for affordable generic drug
The high court decision potentially opens the door for access to a generic version of the patented drug - Risdiplam - at a fraction of the cost marketed by the Swiss pharmaceutical major.
BUSINESS
Donald Trump may find himself in a bind on tariffs on generic drugs
Indian generics saved the US healthcare system $219 billion in 2022 and $1.3 trillion between 2013 and 2022, IQVIA has said
BUSINESS
Bharat Biotech launches $75 million cell & gene therapy facility in Hyderabad
“Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily in developed nations or premium institutions," Dr. Raches Ella, Chief Development Officer, Bharat Biotech, spearheading this CGT initiative, said.
BUSINESS
Indian hospitals focus on other geographies as Bangladesh patient numbers decline
Hospital executives told Moneycontrol that there is a partial recovery in the number of medical visas issued to Bangladesh, even as they have stepped up targeted marketing and outreach efforts and introduced transparent packages to attract patients from other countries.
BUSINESS
Eli Lilly launches popular weight loss drug Mounjaro in India to tackle obesity and diabetes
The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand access to innovative treatments in emerging markets.
BUSINESS
Entero Health acquires Aayu Chemist app, cloud platform MedCords to take on quick commerce rivals
Retail pharmacies in India are facing challenges from quick commerce players, which are reshaping consumer expectations with faster deliveries and digital-first experiences.
BUSINESS
Ambuja Neotia Group lines up Rs 2,000 crore investment in new hospitals, mother-childcare centres in East India
The expansion is being funded through internal accruals and debt. Neotia ruled out immediate equity fundraising, but left the door open for future capital infusion if a strategic acquisition opportunity arises.
BUSINESS
Global pharma giants Eli Lilly, Novo Nordisk launch obesity awareness campaigns, exploring India market potential
Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.
BUSINESS
IPA rejects Ohio University study linking higher adverse events to made in India generics
IPA also refuted the study's reliance on the FDA Adverse Event Reporting System (FAERS) data, stating that FAERS data is observational and does not prove causation between drugs and adverse events.
BUSINESS
Prices of diabetes drug empagliflozin falls by 80-90% as generics enter market
Mankind Pharma, Alkem Laboratories, Glenmark, CORONA Remedies are some of the companies to have launched, making the drug affordable to most Indian patients
BUSINESS
Zydus Lifesciences wants to go beyond the pill, bets big on MedTech with Amplitude buy
India still relies largely on imported devices and implants, and we want to change that, says Dr Sharvil Patel, MD, Zydus Lifesciences.
BUSINESS
Aveo's top executive says no illegal exports of banned drug combinations, blames counterfeiters
Arvind Sharma, Managing Director told Moneycontrol that the exports were done only after getting valid product permissions from the State FDA and required export no-objection certificates
BUSINESS
Indian drugmakers weigh portfolio rejig, manufacturing realignment to survive US tariffs
Indian companies operate on thin EBITDA margins of 5-15% on average for their base business, even a 10% reciprocal tariff as India charges on US exports would make them unviable, if they fail to pass on the increased import duty on to the US consumer
BUSINESS
Metropolis focuses on North India expansion, acquires Agra-based Scientific Pathology
Scientific Pathology was the second acquisition in last three months in North India for Metropolis. The company has acquired Delhi NCR-based specialty cancer testing chain Core Diagnostics for Rs 247 crore through a combination of cash and stock in December last year.
BUSINESS
Cipla Global CEO says drug companies may have to gear up for distributed manufacturing network
'We would like most of the manufacturing to be centric in locations where it is most economic. Looking at every country's ambition to be self sufficient and every country's ambition to be balanced from a tariff perspective or anything else, I actually see a little bit of a difference in the future of how (manufacturing) networks will operate,' said Umang Vohra, Global CEO and MD of Cipla
BUSINESS
Pharma industry body seeks govt to consider tariff cut on US pharma imports to zero
The industry body, which represents large homegrown pharmaceutical companies that have significant exposure to US market, feels that reducing the tariffs on US imports wouldn't cost a lot to India, and may even convince Trump administration to offer relief on tariffs.
COMPANIES
DCGI says streamlining export NoCs, test-licenses to free up regulatory capacity, examining export NoCs given to Aveo Pharma
'We have 10,000 plus manufacturing units, we have 10 lakh of sales outlets, we have 4,000 plus medical devices manufacturing units, we have whole lot of things to be imported and in terms of resources, altogether between Centre and the states, we are around 2,000 regulators to manage this whole dynamics of what I just put in numbers,' says DCGI
